Items Per Page 102550 Year All20242023202220212020201920182017 September 4, 2018 ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference August 20, 2018 ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia August 10, 2018 ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer August 6, 2018 ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update July 3, 2018 ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004 May 17, 2018 ASLAN Pharmaceuticals to Present Two Posters on Varlitinib at ASCO May 4, 2018 ASLAN Pharmaceuticals Prices Initial Public Offering of Its American Depositary Shares April 17, 2018 ASLAN Pharmaceuticals announces presentation of new pre-clinical data on varlitinib in hepatocellular carcinoma at AACR March 26, 2018 ASLAN Pharmaceuticals files for proposed Initial Public Offering in the U.S. January 31, 2018 ASLAN Pharmaceuticals sponsors Cholangiocarcinoma Foundation Annual Conference 2018
September 4, 2018 ASLAN Pharmaceuticals to Present at HC Wainwright 20th Annual Global Investment Conference
August 20, 2018 ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia
August 10, 2018 ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer
August 6, 2018 ASLAN Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
July 3, 2018 ASLAN Pharmaceuticals Submits Clinical Trial Authorisation Application for First in Man Studies for ASLAN004
April 17, 2018 ASLAN Pharmaceuticals announces presentation of new pre-clinical data on varlitinib in hepatocellular carcinoma at AACR